{"id":"W4200407033","doi":"10.1038/s41591-021-01539-8","title":"Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial","year":2021,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":147,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Stanford Cancer Institute; National Center for Advancing Translational Sciences; Genentech; National Institutes of Health; Astellas Pharma; Swedish Orphan Biovitrum; Novo Nordisk; National Heart, Lung, and Blood Institute; Scheme for Promotion of Academic and Research Collaboration; Alexion Pharmaceuticals; Apellis Pharmaceuticals; Sierra Oncology; F. Hoffmann-La Roche; CTI Biopharma; Pfizer; Incyte; Celgene; National Cancer Institute; Gilead Sciences; Chugai Pharmaceutical; ARUP Laboratories; José Carreras Leukämie-Stiftung; Amgen; Cilag; University of Texas MD Anderson Cancer Center; Agios Pharmaceuticals; Bristol-Myers Squibb","keywords":"Systemic mastocytosis; Medicine; Clinical endpoint; Internal medicine; Interim analysis; Adverse effect; Neutropenia; Gastroenterology; Tryptase; Anemia; Phases of clinical research; Clinical trial; Oncology; Bone marrow; Mast cell; Immunology; Chemotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003634225,0.0001059797,0.0006321018,0.0001803517,0.00002660312,0.000001034635,0.0001390374,0.0002677458,0.0004626311],"category_scores_gemma":[0.0003369908,0.00006528649,0.00008796011,0.0006429759,0.0001927784,0.00001451066,0.00004516672,0.0004490335,6.86245e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001469099,"about_ca_system_score_gemma":0.00003801099,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001999067,"about_ca_topic_score_gemma":0.00007395874,"domain_scores_codex":[0.9989026,0.0002364887,0.0004773498,0.0001996268,0.00006435833,0.0001195756],"domain_scores_gemma":[0.9991801,0.000226851,0.0002013887,0.0002914371,0.00008923581,0.00001093823],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0193083,0.0006749255,0.0006773805,0.0002024152,0.000749108,0.00001925634,0.002498705,0.000008525051,0.9648416,0.0008850163,0.0003985527,0.009736211],"study_design_scores_gemma":[0.6580858,0.00476652,0.05803794,0.003513308,0.006392253,0.000266684,0.009864748,0.00004456186,0.196951,0.00006631016,0.06144388,0.0005669977],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762998,0.02148072,0.00003191708,0.0004706538,0.0005047482,0.0002828064,0.00005020458,0.000004650105,0.000874523],"genre_scores_gemma":[0.9990515,0.0002509165,0.00001764041,0.0001728568,0.00003121495,0.000006639225,0.0001310176,0.000004626613,0.000333629],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7678906,"threshold_uncertainty_score":0.5065486,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009858173662321577,"score_gpt":0.2884010356378187,"score_spread":0.2785428619754971,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}